Rhombencephalitis associated with isolated Zic4-antibodies in Paraneoplastic cerebellar degeneration: a case report.


Journal

BMC neurology
ISSN: 1471-2377
Titre abrégé: BMC Neurol
Pays: England
ID NLM: 100968555

Informations de publication

Date de publication:
25 May 2020
Historique:
received: 14 02 2020
accepted: 14 05 2020
entrez: 27 5 2020
pubmed: 27 5 2020
medline: 25 9 2020
Statut: epublish

Résumé

Cerebellar degeneration as a consequence of a malignancy is a rare condition most commonly related to the presence of anti-Yo, anti-Hu, and anti-Tr/DNER antibodies. In recent years, several reports have indicated Zinc-finger protein 4 (Zic4) antibodies being associated with paraneoplastic cerebellar degeneration (PCD) in patients with small cell lung carcinoma. However, the prevalence and the significance of Zic4-antibodies may be underestimated due to their co-occurrence with more frequent antibodies such as anti-Hu. A literature review of isolated Zic4 mediated paraneoplastic syndromes yielded 14 cases reporting mainly benign clinical courses when treated early. We present the case of a 67-year-old woman with progressive Zic4 antibody mediated PCD and rhombencephalitis. Immunomodulatory treatment, including intravenous methylprednisolone, plasmaphereses, and intravenous immunoglobulin (IVIG) was administered. Small cell lung cancer (SCLC) was detected, lobectomy performed and cyclophosphamide started. Despite this considerable therapeutic effort, rhombencephalitis led to defiant dysautonomia. Paraneoplastic syndromes related to isolated Zic4 antibodies are rare and typically show a benign clinical course. Here, we present the first case of a rapidly progressive isolated Zic4 associated PCD and rhombencephalitis. Despite considerable therapeutic efforts, the patient passed away on autonomic dysfunction, highlighting the significance of Zic4 associated disease.

Sections du résumé

BACKGROUND BACKGROUND
Cerebellar degeneration as a consequence of a malignancy is a rare condition most commonly related to the presence of anti-Yo, anti-Hu, and anti-Tr/DNER antibodies. In recent years, several reports have indicated Zinc-finger protein 4 (Zic4) antibodies being associated with paraneoplastic cerebellar degeneration (PCD) in patients with small cell lung carcinoma. However, the prevalence and the significance of Zic4-antibodies may be underestimated due to their co-occurrence with more frequent antibodies such as anti-Hu. A literature review of isolated Zic4 mediated paraneoplastic syndromes yielded 14 cases reporting mainly benign clinical courses when treated early.
CASE PRESENTATION METHODS
We present the case of a 67-year-old woman with progressive Zic4 antibody mediated PCD and rhombencephalitis. Immunomodulatory treatment, including intravenous methylprednisolone, plasmaphereses, and intravenous immunoglobulin (IVIG) was administered. Small cell lung cancer (SCLC) was detected, lobectomy performed and cyclophosphamide started. Despite this considerable therapeutic effort, rhombencephalitis led to defiant dysautonomia.
CONCLUSION CONCLUSIONS
Paraneoplastic syndromes related to isolated Zic4 antibodies are rare and typically show a benign clinical course. Here, we present the first case of a rapidly progressive isolated Zic4 associated PCD and rhombencephalitis. Despite considerable therapeutic efforts, the patient passed away on autonomic dysfunction, highlighting the significance of Zic4 associated disease.

Identifiants

pubmed: 32450842
doi: 10.1186/s12883-020-01788-z
pii: 10.1186/s12883-020-01788-z
pmc: PMC7249364
doi:

Substances chimiques

Autoantibodies 0
Nerve Tissue Proteins 0
Transcription Factors 0
ZIC4 protein, human 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

208

Références

Clin Genet. 2005 Apr;67(4):290-6
pubmed: 15733262
Noro Psikiyatr Ars. 2018 May 04;55(2):189-194
pubmed: 30057463
Lancet Neurol. 2008 Apr;7(4):327-40
pubmed: 18339348
Neurology. 2002 Dec 24;59(12):1985-7
pubmed: 12499499
J Neurol Sci. 2018 Jan 15;384:36-37
pubmed: 29249374
J Neuroimmunol. 2008 Sep 15;201-202:163-5
pubmed: 18639938
Brain. 2001 Jun;124(Pt 6):1138-48
pubmed: 11353730
Neurol Neuroimmunol Neuroinflamm. 2020 Jan 17;7(3):
pubmed: 31953318
Neurology. 2004 Mar 9;62(5):778-82
pubmed: 15007130
Curr Opin Oncol. 2015 Nov;27(6):489-95
pubmed: 26335665
Clin Neurol Neurosurg. 2018 May;168:72-76
pubmed: 29525731
Arch Neurol. 2011 Aug;68(8):1073
pubmed: 21825246
Neurology. 1992 Oct;42(10):1931-7
pubmed: 1407575

Auteurs

Philipp A Loehrer (PA)

Department of Neurology, University Hospital of Gießen and Marburg, Marburg, Germany. philipp.loehrer@uk-gm.de.

Lars Timmermann (L)

Department of Neurology, University Hospital of Gießen and Marburg, Marburg, Germany.

Anika Pehl (A)

Institute of Pathology, University Hospital of Gießen and Marburg, Marburg, Germany.

Corinna I Bien (CI)

Laboratory Krone, Bad Salzuflen, Germany.

Andreas Pfestroff (A)

Department of Nuclear Medicine, University Hospital of Gießen and Marburg, Marburg, Germany.

David J Pedrosa (DJ)

Department of Neurology, University Hospital of Gießen and Marburg, Marburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH